Heart failure with preserved ejection fraction (HFpEF) is present in nearly half of patients
with heart failure. The prevalence of heart failure with normal or near-normal ejection …

Aims The efficacy and safety of sacubitril/valsartan for patients with heart failure with
preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the …

Introduction: Sacubitril-valsartan is a combination drug that contains the neprilysin inhibitor
sacubitril and angiotensin II receptor blocker valsartan. In 2015, the US Food and Drug …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

We performed a meta-analysis investigating the efficacy and adverse effects of sacubitril–
valsartan in various types of heart failure including more recent studies and a larger sample …

Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical condition
characterized by large pathophysiology heterogeneity with lack of effective therapies as …

This study aimed at analyzing the clinical profile of real-world patients with heart failure with
reduced ejection fraction (HFrEF) and evaluating the safety and efficacy of …

Abstract Aims Sacubitril/Valsartan (Sac/Val) was proven more effective than enalapril for
symptomatic patients with heart failure (HF) with reduced ejection fraction (HFrEF). This …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …